Pregabalin Capsule
Product Images NDC 71335-1758

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1758). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351758)

Label for Pregabalin 75 mg (CV) capsules by Bryant Ranch Prepack. The label indicates the capsules are white and orange with imprint A009;PREG75. It is compared to Lyrica 75 mg (CV) capsule by Alkem Laboratories Ltd. The package contains 30 capsules with storage instructions at 20°C-25°C (68°F-77°F) and a safety warning to keep drugs out of reach of children. The NDC is 71335-1758-1.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This image shows a formula for calculating creatinine clearance (CLCr) based on age, weight, and serum creatinine levels, with a multiplier adjustment for female patients. It appears on a drug information or prescribing text panel.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar chart presenting responder rates (%) in two clinical studies (Study E1 and Study E3) for Pregabalin capsules at various dosages compared to placebo. Study E1 shows responder rates for placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day dosed twice daily (BID). Study E3 shows rates for placebo, 600 mg/day BID, and 600 mg/day three times daily (TID). Asterisks denote statistically significant differences versus placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as median percent change from baseline versus dose (mg/day) of pregabalin across multiple studies (E1 BID, E2 TID, E3 BID, E3 TID). The graph shows dose-dependent seizure reduction with significant p-values indicated at various dose points, comparing placebo to different dosing regimens.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline for different pregabalin doses (200 mg, 100 mg, 25 mg three times a day) and placebo. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percent of patients improved. Multiple curves depict differences in patient response among treatment groups.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph showing the percent of subjects improved over a range of percentage improvement from baseline to Week 12 BOCF. Two lines compare Pregabalin and Placebo, with the Pregabalin line consistently higher than the Placebo line, indicating greater subject improvement in the Pregabalin group.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line chart depicting the percent of subjects improved over time from baseline to week 16 using the brief pain inventory questionnaire (BPIQ). The x-axis represents the percent improvement from baseline to week 16 BPIQ, ranging approximately from 0 to 100. The y-axis represents the percent of subjects improved, ranging from 0 to 100%. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, with the Pregabalin group consistently showing higher improvement percentages than placebo.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved, showing two lines representing Pregabalin 100 mg three times a day and placebo. The horizontal axis is percent improvement in pain from baseline, and the vertical axis is percent of patients improved.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

Line graph depicting percentage of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, showing treatment effects over different pain improvement levels.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis indicates the percent of patients improved (0 to 100%), and the x-axis shows percent improvement in pain from baseline (0 to 100%).*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph comparing percent improvement in pain from baseline against the percent of patients improved for Pregabalin 100 mg three times daily, Pregabalin 50 mg three times daily, and placebo groups. The graph displays three trend lines showing varying levels of pain improvement across patient groups.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 600 mg, 450 mg, 300 mg daily doses and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percent of patients improved, with multiple lines indicating different dosing groups.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve comparing estimated percentage of subjects without LTR over 180 days between Pregabalin and Placebo groups. The graph displays days on the x-axis and estimated percentage of subjects without LTR on the y-axis, with separate lines for Pregabalin and Placebo treatments.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin, showing its molecular arrangement featuring an amino group (NH2) and a carboxylic acid group (CO2H) attached to a branched carbon backbone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.